SCYNEXIS (SCYX) to Release Earnings on Thursday

SCYNEXIS (NASDAQ:SCYX) will likely be issuing its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $10.19 million for the quarter.

SCYNEXIS (NASDAQ:SCYX) last issued its quarterly earnings data on Wednesday, March 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.13. The firm had revenue of $0.98 million during the quarter. SCYNEXIS had a negative net margin of 425.41% and a negative return on equity of 66.21%.

SCYNEXIS Stock Performance

Shares of NASDAQ SCYX opened at $1.07 on Thursday. The stock has a market cap of $41.71 million, a P/E ratio of -1.45 and a beta of 1.67. The firm has a 50 day moving average price of $1.07 and a 200 day moving average price of $1.24. SCYNEXIS has a 52-week low of $0.82 and a 52-week high of $3.07.

Wall Street Analyst Weigh In

Separately, StockNews.com cut shares of SCYNEXIS from a “hold” rating to a “sell” rating in a report on Thursday, March 13th.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.